Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic biology company that completed its public listing in September 2021 through a merger with Soaring Eagle Acquisition Corp., a SPAC sponsored by Eagle Equity Partners. The deal brought Ginkgo to market as one of the more prominent biotech-sector SPAC transactions of that year, with the combined entity trading under the DNA ticker on the New York Stock Exchange. The company operates in the synthetic biology and industrial biotechnology space, offering cell programming and biosecurity services. In April 2026, Ginkgo filed a DEF 14A definitive proxy statement with the SEC, covering matters put to a shareholder vote at its annual meeting. For complete filing history, ownership data, and deal metrics on Ginkgo Bioworks and hundreds of other SPAC transactions, sign up for full access at SpacDesk.